Trial Outcomes & Findings for A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) (NCT NCT02706951)
NCT ID: NCT02706951
Last Updated: 2024-01-30
Results Overview
The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 14. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
648 participants
Primary outcome timeframe
Baseline and week 14
Results posted on
2024-01-30
Participant Flow
A total of 648 participants with rheumatoid arthritis (RA) on a stable dose of methotrexate (MTX) were randomized at 138 study sites located in 24 countries.
Participants were randomized in a 2:2:1:1 ratio to 1 of 4 groups: * Upadacitinib 30 mg (Periods 1 and 2) * Upadacitinib 15 mg (Periods 1 and 2) * MTX (Period 1) → upadacitinib 30 mg (Period 2) * MTX (Period 1) → upadacitinib 15 mg (Period 2) Randomization was stratified by geographic region. The MTX groups were pooled for Week 14 analyses. Starting with Amend. 5 \& during Period 2, all participants received open-label upadacitinib 15 mg, including participants receiving upadacitinib 30 mg
Participant milestones
| Measure |
Period 1: Methotrexate
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily (QD) for 14 weeks in Period 1.
|
Period 1: Upadacitinib 15 mg
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Period 1: Upadacitinib 30 mg
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Period 2: Upadacitinib 15 mg
Continuing Period 1 participants that were randomized into the upadacitinib 15 mg once daily arm combined with Period 1 Methotrexate (MTX) participants that were randomized to receive upadacitinib 15 mg once daily in Period 2
|
Period 2: Upadacitinib 30 mg
Continuing Period 1 participants that were randomized into the upadacitinib 30 mg once daily arm combined with Period 1 Methotrexate (MTX) participants that were randomized to receive upadacitinib 30 mg once daily in Period 2
|
|---|---|---|---|---|---|
|
Period 1
STARTED
|
216
|
217
|
215
|
0
|
0
|
|
Period 1
COMPLETED
|
203
|
201
|
205
|
0
|
0
|
|
Period 1
NOT COMPLETED
|
13
|
16
|
10
|
0
|
0
|
|
Period 2
STARTED
|
0
|
0
|
0
|
302
|
300
|
|
Period 2
COMPLETED
|
0
|
0
|
0
|
184
|
180
|
|
Period 2
NOT COMPLETED
|
0
|
0
|
0
|
118
|
120
|
Reasons for withdrawal
| Measure |
Period 1: Methotrexate
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily (QD) for 14 weeks in Period 1.
|
Period 1: Upadacitinib 15 mg
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Period 1: Upadacitinib 30 mg
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Period 2: Upadacitinib 15 mg
Continuing Period 1 participants that were randomized into the upadacitinib 15 mg once daily arm combined with Period 1 Methotrexate (MTX) participants that were randomized to receive upadacitinib 15 mg once daily in Period 2
|
Period 2: Upadacitinib 30 mg
Continuing Period 1 participants that were randomized into the upadacitinib 30 mg once daily arm combined with Period 1 Methotrexate (MTX) participants that were randomized to receive upadacitinib 30 mg once daily in Period 2
|
|---|---|---|---|---|---|
|
Period 1
Adverse Event
|
1
|
5
|
3
|
0
|
0
|
|
Period 1
Withdrawal by Subject
|
10
|
6
|
6
|
0
|
0
|
|
Period 1
Lost to Follow-up
|
0
|
4
|
1
|
0
|
0
|
|
Period 1
Other
|
2
|
1
|
0
|
0
|
0
|
|
Period 2
Adverse Event
|
0
|
0
|
0
|
25
|
34
|
|
Period 2
Withdrawal by Subject
|
0
|
0
|
0
|
38
|
44
|
|
Period 2
Lost to Follow-up
|
0
|
0
|
0
|
17
|
9
|
|
Period 2
COVID-19 Related
|
0
|
0
|
0
|
1
|
2
|
|
Period 2
Other
|
0
|
0
|
0
|
37
|
31
|
Baseline Characteristics
Participants with available data
Baseline characteristics by cohort
| Measure |
Methotrexate
n=216 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=217 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=215 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Total
n=648 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
55.3 years
STANDARD_DEVIATION 11.12 • n=216 Participants
|
54.5 years
STANDARD_DEVIATION 12.20 • n=217 Participants
|
53.1 years
STANDARD_DEVIATION 12.72 • n=215 Participants
|
54.3 years
STANDARD_DEVIATION 12.05 • n=648 Participants
|
|
Age, Customized
< 40 years
|
23 Participants
n=216 Participants
|
28 Participants
n=217 Participants
|
31 Participants
n=215 Participants
|
82 Participants
n=648 Participants
|
|
Age, Customized
40 - 64 years
|
148 Participants
n=216 Participants
|
147 Participants
n=217 Participants
|
141 Participants
n=215 Participants
|
436 Participants
n=648 Participants
|
|
Age, Customized
≥ 65 years
|
45 Participants
n=216 Participants
|
42 Participants
n=217 Participants
|
43 Participants
n=215 Participants
|
130 Participants
n=648 Participants
|
|
Sex: Female, Male
Female
|
179 Participants
n=216 Participants
|
174 Participants
n=217 Participants
|
170 Participants
n=215 Participants
|
523 Participants
n=648 Participants
|
|
Sex: Female, Male
Male
|
37 Participants
n=216 Participants
|
43 Participants
n=217 Participants
|
45 Participants
n=215 Participants
|
125 Participants
n=648 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
50 Participants
n=216 Participants
|
52 Participants
n=217 Participants
|
54 Participants
n=215 Participants
|
156 Participants
n=648 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
166 Participants
n=216 Participants
|
165 Participants
n=217 Participants
|
161 Participants
n=215 Participants
|
492 Participants
n=648 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=216 Participants
|
0 Participants
n=217 Participants
|
0 Participants
n=215 Participants
|
0 Participants
n=648 Participants
|
|
Race/Ethnicity, Customized
White
|
176 Participants
n=216 Participants
|
173 Participants
n=217 Participants
|
180 Participants
n=215 Participants
|
529 Participants
n=648 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
11 Participants
n=216 Participants
|
15 Participants
n=217 Participants
|
9 Participants
n=215 Participants
|
35 Participants
n=648 Participants
|
|
Race/Ethnicity, Customized
American Indian/Alaska Native
|
3 Participants
n=216 Participants
|
4 Participants
n=217 Participants
|
3 Participants
n=215 Participants
|
10 Participants
n=648 Participants
|
|
Race/Ethnicity, Customized
Asian
|
24 Participants
n=216 Participants
|
24 Participants
n=217 Participants
|
21 Participants
n=215 Participants
|
69 Participants
n=648 Participants
|
|
Race/Ethnicity, Customized
Multiple
|
2 Participants
n=216 Participants
|
1 Participants
n=217 Participants
|
2 Participants
n=215 Participants
|
5 Participants
n=648 Participants
|
|
Geographic Region
North America
|
64 Participants
n=216 Participants
|
64 Participants
n=217 Participants
|
64 Participants
n=215 Participants
|
192 Participants
n=648 Participants
|
|
Geographic Region
South/Central America
|
31 Participants
n=216 Participants
|
30 Participants
n=217 Participants
|
30 Participants
n=215 Participants
|
91 Participants
n=648 Participants
|
|
Geographic Region
Western Europe
|
8 Participants
n=216 Participants
|
8 Participants
n=217 Participants
|
8 Participants
n=215 Participants
|
24 Participants
n=648 Participants
|
|
Geographic Region
Eastern Europe
|
79 Participants
n=216 Participants
|
80 Participants
n=217 Participants
|
80 Participants
n=215 Participants
|
239 Participants
n=648 Participants
|
|
Geographic Region
Asia - Japan
|
22 Participants
n=216 Participants
|
22 Participants
n=217 Participants
|
21 Participants
n=215 Participants
|
65 Participants
n=648 Participants
|
|
Geographic Region
Other
|
12 Participants
n=216 Participants
|
13 Participants
n=217 Participants
|
12 Participants
n=215 Participants
|
37 Participants
n=648 Participants
|
|
Duration of RA Diagnosis
|
5.8 years
STANDARD_DEVIATION 6.63 • n=216 Participants
|
7.5 years
STANDARD_DEVIATION 8.88 • n=217 Participants
|
6.5 years
STANDARD_DEVIATION 6.98 • n=215 Participants
|
6.6 years
STANDARD_DEVIATION 7.58 • n=648 Participants
|
|
Tender Joint Count
|
25.2 joints
STANDARD_DEVIATION 15.99 • n=216 Participants
|
24.5 joints
STANDARD_DEVIATION 15.10 • n=217 Participants
|
24.8 joints
STANDARD_DEVIATION 15.19 • n=215 Participants
|
24.8 joints
STANDARD_DEVIATION 15.41 • n=648 Participants
|
|
Swollen Joint Count
|
16.9 joints
STANDARD_DEVIATION 11.52 • n=216 Participants
|
16.4 joints
STANDARD_DEVIATION 10.94 • n=217 Participants
|
16.9 joints
STANDARD_DEVIATION 10.23 • n=215 Participants
|
16.7 joints
STANDARD_DEVIATION 10.90 • n=648 Participants
|
|
Patient's Assessment of Pain
|
62.5 mm
STANDARD_DEVIATION 21.26 • n=216 Participants • Participants with available data
|
62.3 mm
STANDARD_DEVIATION 22.53 • n=216 Participants • Participants with available data
|
61.9 mm
STANDARD_DEVIATION 22.12 • n=215 Participants • Participants with available data
|
62.3 mm
STANDARD_DEVIATION 21.94 • n=647 Participants • Participants with available data
|
|
Patient's Global Assessment of Disease Activity
|
59.6 mm
STANDARD_DEVIATION 21.78 • n=216 Participants • Participants with available data
|
62.2 mm
STANDARD_DEVIATION 22.29 • n=216 Participants • Participants with available data
|
59.4 mm
STANDARD_DEVIATION 22.79 • n=215 Participants • Participants with available data
|
60.4 mm
STANDARD_DEVIATION 22.29 • n=647 Participants • Participants with available data
|
|
Physician's Global Assessment of Disease Activity
|
62.1 mm
STANDARD_DEVIATION 17.47 • n=200 Participants • Participants with available data
|
65.7 mm
STANDARD_DEVIATION 18.49 • n=209 Participants • Participants with available data
|
62.6 mm
STANDARD_DEVIATION 17.81 • n=202 Participants • Participants with available data
|
63.5 mm
STANDARD_DEVIATION 17.98 • n=611 Participants • Participants with available data
|
|
Health Assessment Questionnaire - Disability Index (HAQ-DI)
|
1.5 units on a scale
STANDARD_DEVIATION 0.66 • n=216 Participants • Participants with available data
|
1.5 units on a scale
STANDARD_DEVIATION 0.66 • n=216 Participants • Participants with available data
|
1.5 units on a scale
STANDARD_DEVIATION 0.65 • n=215 Participants • Participants with available data
|
1.5 units on a scale
STANDARD_DEVIATION 0.66 • n=647 Participants • Participants with available data
|
|
High-sensitivity C-reactive Protein (hsCRP)
|
14.5 mg/L
STANDARD_DEVIATION 17.33 • n=216 Participants
|
14.0 mg/L
STANDARD_DEVIATION 16.49 • n=217 Participants
|
16.3 mg/L
STANDARD_DEVIATION 20.77 • n=215 Participants
|
14.9 mg/L
STANDARD_DEVIATION 18.28 • n=648 Participants
|
|
Disease Activity Score 28 Based on CRP (DAS28[CRP])
|
5.6 units on a scale
STANDARD_DEVIATION 1.04 • n=216 Participants • Participants with available data
|
5.6 units on a scale
STANDARD_DEVIATION 0.92 • n=216 Participants • Participants with available data
|
5.6 units on a scale
STANDARD_DEVIATION 1.06 • n=215 Participants • Participants with available data
|
5.6 units on a scale
STANDARD_DEVIATION 1.01 • n=647 Participants • Participants with available data
|
PRIMARY outcome
Timeframe: Baseline and week 14Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 14 or for whom ACR data were missing at Week 14 were considered non-responders.
The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 14. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Outcome measures
| Measure |
Methotrexate
n=216 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=217 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=215 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
|---|---|---|---|
|
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14
|
41.2 percentage of participants
Interval 34.6 to 47.8
|
67.7 percentage of participants
Interval 61.5 to 74.0
|
71.2 percentage of participants
Interval 65.1 to 77.2
|
PRIMARY outcome
Timeframe: Week 14Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 14 or for whom DAS28 data were missing at Week 14 were considered non-responders.
The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 14. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.
Outcome measures
| Measure |
Methotrexate
n=216 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=217 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=215 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
|---|---|---|---|
|
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14
|
19.4 percentage of participants
Interval 14.2 to 24.7
|
44.7 percentage of participants
Interval 38.1 to 51.3
|
53.0 percentage of participants
Interval 46.4 to 59.7
|
SECONDARY outcome
Timeframe: Baseline to week 14Population: Full analysis set participants with available data at baseline; multiple imputation was used for missing post-baseline data.
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.
Outcome measures
| Measure |
Methotrexate
n=215 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=215 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=213 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
|---|---|---|---|
|
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 14
|
-1.20 scores on a scale
Interval -1.39 to -1.01
|
-2.29 scores on a scale
Interval -2.48 to -2.1
|
-2.61 scores on a scale
Interval -2.8 to -2.41
|
SECONDARY outcome
Timeframe: Baseline to week 14Population: Full analysis set participants with available data at baseline; multiple imputation was used for missing data.
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
Outcome measures
| Measure |
Methotrexate
n=216 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=216 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=215 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
|---|---|---|---|
|
Change From Baseline in Heath Assessment Questionnaire and Disability Index (HAQ-DI) at Week 14
|
-0.32 scores on a scale
Interval -0.41 to -0.23
|
-0.65 scores on a scale
Interval -0.73 to -0.56
|
-0.73 scores on a scale
Interval -0.82 to -0.64
|
SECONDARY outcome
Timeframe: Baseline to week 14Population: Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 14 was used.
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.
Outcome measures
| Measure |
Methotrexate
n=195 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=200 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=201 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
|---|---|---|---|
|
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 14
|
4.32 scores on a scale
Interval 3.19 to 5.44
|
8.28 scores on a scale
Interval 7.17 to 9.4
|
10.19 scores on a scale
Interval 9.07 to 11.3
|
SECONDARY outcome
Timeframe: Week 14Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 14 or for whom DAS28 data were missing at Week 14 were considered non-responders
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than 2.6 indicates clinical remission.
Outcome measures
| Measure |
Methotrexate
n=216 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=217 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=215 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
|---|---|---|---|
|
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 14
|
8.3 percentage of participants
Interval 4.6 to 12.0
|
28.1 percentage of participants
Interval 22.1 to 34.1
|
40.5 percentage of participants
Interval 33.9 to 47.0
|
SECONDARY outcome
Timeframe: Baseline to week 14Population: Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 14 was used.
Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days. A negative change from Baseline indicates improvement.
Outcome measures
| Measure |
Methotrexate
n=196 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=199 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=202 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
|---|---|---|---|
|
Change From Baseline in Duration of Morning Stiffness at Week 14
|
-53.03 minutes
Interval -72.18 to -33.88
|
-94.56 minutes
Interval -113.57 to -75.54
|
-102.34 minutes
Interval -121.24 to -83.45
|
SECONDARY outcome
Timeframe: Baseline and week 14Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 14 or for whom ACR data were missing at Week 14 were considered non-responders.
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Outcome measures
| Measure |
Methotrexate
n=216 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=217 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=215 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
|---|---|---|---|
|
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 14
|
15.3 percentage of participants
Interval 10.5 to 20.1
|
41.9 percentage of participants
Interval 35.4 to 48.5
|
52.1 percentage of participants
Interval 45.4 to 58.8
|
SECONDARY outcome
Timeframe: Baseline and week 14Population: Full analysis set; participants who prematurely discontinued from study drug prior to Week 14 or for whom ACR data were missing at Week 14 were considered non-responders.
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Outcome measures
| Measure |
Methotrexate
n=216 Participants
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=217 Participants
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Upadacitinib 30 mg
n=215 Participants
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
|---|---|---|---|
|
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 14
|
2.8 percentage of participants
Interval 0.6 to 5.0
|
22.6 percentage of participants
Interval 17.0 to 28.1
|
33.0 percentage of participants
Interval 26.7 to 39.3
|
Adverse Events
Period 1: Methotrexate
Serious events: 7 serious events
Other events: 49 other events
Deaths: 0 deaths
Period 1: Upadacitinib 15 mg
Serious events: 11 serious events
Other events: 43 other events
Deaths: 0 deaths
Period 1: Upadacitinib 30 mg
Serious events: 6 serious events
Other events: 51 other events
Deaths: 0 deaths
Periods 1+2: Upadacitinib 15 mg
Serious events: 95 serious events
Other events: 219 other events
Deaths: 7 deaths
Periods 1+ 2: Upadacitinib 30 mg
Serious events: 75 serious events
Other events: 211 other events
Deaths: 5 deaths
Period 2: Upadacitinib 15 mg Switched From Upadacitinib 30 mg
Serious events: 22 serious events
Other events: 82 other events
Deaths: 4 deaths
Serious adverse events
| Measure |
Period 1: Methotrexate
n=216 participants at risk
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Period 1: Upadacitinib 15 mg
n=217 participants at risk
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Period 1: Upadacitinib 30 mg
n=215 participants at risk
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Periods 1+2: Upadacitinib 15 mg
n=318 participants at risk
Participants randomized to receive upadacitinib 15 mg once daily
|
Periods 1+ 2: Upadacitinib 30 mg
n=311 participants at risk
Participants randomized to receive upadacitinib 30 mg once daily
|
Period 2: Upadacitinib 15 mg Switched From Upadacitinib 30 mg
n=205 participants at risk
Starting with Amendment 5, all participants will receive open-label upadacitinib 15 mg once daily, including those currently on upadacitinib 30 mg once daily
|
|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Blood and lymphatic system disorders
Bone marrow oedema
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Blood and lymphatic system disorders
Lymphadenitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Blood and lymphatic system disorders
Normocytic anaemia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Atrial fibrillation
|
0.46%
1/216 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.6%
5/318 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Atrial flutter
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Atrioventricular block first degree
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Atrioventricular block second degree
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.94%
3/318 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.47%
1/215 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.3%
4/311 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Palpitations
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Paroxysmal atrioventricular block
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Ear and labyrinth disorders
Mixed deafness
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Eye disorders
Macular hole
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Eye disorders
Retinal detachment
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.94%
3/318 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Gastrointestinal inflammation
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Intestinal pseudo-obstruction
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
General disorders
Chest pain
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
General disorders
General physical health deterioration
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
General disorders
Impaired healing
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
General disorders
Pyrexia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
General disorders
Sudden cardiac death
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
General disorders
Sudden death
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Hepatobiliary disorders
Bile duct stone
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.93%
2/216 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Hepatobiliary disorders
Cholecystitis chronic
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.47%
1/215 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Hepatobiliary disorders
Hepatitis acute
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Hepatobiliary disorders
Hepatotoxicity
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Abscess limb
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Appendicitis perforated
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Arthritis bacterial
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Bartholin's abscess
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Bronchiolitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Bronchitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.3%
4/318 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Bursitis infective
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Sepsis syndrome
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
COVID-19
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.94%
3/318 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.98%
2/205 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
COVID-19 pneumonia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.5%
8/318 • Number of events 8 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.3%
4/311 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
3.4%
7/205 • Number of events 7 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Cellulitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.96%
3/311 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Gangrene
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Helicobacter gastritis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.96%
3/311 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Infected skin ulcer
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Influenza
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Oral herpes
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Osteomyelitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Pneumonia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
3.8%
12/318 • Number of events 12 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.3%
4/311 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Pneumonia viral
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Pyelonephritis chronic
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Sepsis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Staphylococcal osteomyelitis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.96%
3/311 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Urosepsis
|
0.46%
1/216 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Fibula fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Gastrointestinal injury
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.47%
1/215 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.3%
4/311 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.47%
1/215 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Ligament rupture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Lower limb fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Periprosthetic fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Pneumothorax traumatic
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Stress fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Thoracic vertebral fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Injury, poisoning and procedural complications
Toxicity to various agents
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Costochondritis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.46%
1/216 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.6%
5/318 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.96%
3/311 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.98%
2/205 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Osteoporotic fracture
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.47%
1/215 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.94%
3/318 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.6%
5/311 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Scoliosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Spinal stenosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Spondylolisthesis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.47%
1/215 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign lung neoplasm
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon adenoma
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of nipple
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour benign
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal adenocarcinoma
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Intensive care unit acquired weakness
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Intracranial aneurysm
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Ischaemic stroke
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.47%
1/215 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Lacunar stroke
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Metabolic encephalopathy
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Sciatica
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Syncope
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Nervous system disorders
Transient global amnesia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Product Issues
Device dislocation
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Product Issues
Device issue
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Product Issues
Device loosening
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Psychiatric disorders
Major depression
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Renal and urinary disorders
Cystitis noninfective
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.46%
1/216 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Renal and urinary disorders
Nephropathy toxic
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Renal and urinary disorders
Pelvi-ureteric obstruction
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Renal and urinary disorders
Renal impairment
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Reproductive system and breast disorders
Cystocele
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Hydrothorax
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Obstructive airways disorder
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.94%
3/318 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.98%
2/205 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Surgical and medical procedures
Abortion induced
|
0.46%
1/216 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Vascular disorders
Aortic stenosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Vascular disorders
Hypertension
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.63%
2/318 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Vascular disorders
Hypertensive crisis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Vascular disorders
Hypotension
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.31%
1/318 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/311 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Vascular disorders
Peripheral artery aneurysm
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Vascular disorders
Peripheral artery thrombosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Vascular disorders
Superficial vein thrombosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/318 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.32%
1/311 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/205 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
Other adverse events
| Measure |
Period 1: Methotrexate
n=216 participants at risk
Participants randomized to receive up to 25 mg methotrexate once a week and placebo to upadacitinib once daily for 14 weeks in Period 1.
|
Period 1: Upadacitinib 15 mg
n=217 participants at risk
Participants randomized to receive upadacitinib 15 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Period 1: Upadacitinib 30 mg
n=215 participants at risk
Participants randomized to receive upadacitinib 30 mg once daily and placebo to methotrexate once a week for 14 weeks in Period 1.
|
Periods 1+2: Upadacitinib 15 mg
n=318 participants at risk
Participants randomized to receive upadacitinib 15 mg once daily
|
Periods 1+ 2: Upadacitinib 30 mg
n=311 participants at risk
Participants randomized to receive upadacitinib 30 mg once daily
|
Period 2: Upadacitinib 15 mg Switched From Upadacitinib 30 mg
n=205 participants at risk
Starting with Amendment 5, all participants will receive open-label upadacitinib 15 mg once daily, including those currently on upadacitinib 30 mg once daily
|
|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.93%
2/216 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
6.3%
20/318 • Number of events 27 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
5.8%
18/311 • Number of events 20 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
3.4%
7/205 • Number of events 7 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.4%
3/215 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.8%
9/318 • Number of events 17 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
5.8%
18/311 • Number of events 27 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.5%
3/205 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Bronchitis
|
3.2%
7/216 • Number of events 7 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.8%
4/217 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.9%
4/215 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
12.3%
39/318 • Number of events 50 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
12.9%
40/311 • Number of events 45 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.4%
5/205 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
COVID-19
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
6.6%
21/318 • Number of events 21 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.64%
2/311 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
9.8%
20/205 • Number of events 20 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Herpes zoster
|
0.46%
1/216 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.4%
3/217 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.3%
5/215 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
10.1%
32/318 • Number of events 33 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
10.3%
32/311 • Number of events 35 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.9%
6/205 • Number of events 6 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Influenza
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
4.7%
15/318 • Number of events 15 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
5.8%
18/311 • Number of events 19 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.98%
2/205 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Latent tuberculosis
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
7.9%
25/318 • Number of events 25 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
5.1%
16/311 • Number of events 16 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.4%
5/205 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Nasopharyngitis
|
3.2%
7/216 • Number of events 7 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.8%
4/217 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.9%
4/215 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
17.6%
56/318 • Number of events 79 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
12.2%
38/311 • Number of events 65 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
3.4%
7/205 • Number of events 8 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Upper respiratory tract infection
|
6.0%
13/216 • Number of events 16 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
4.1%
9/217 • Number of events 9 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.8%
6/215 • Number of events 6 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
11.9%
38/318 • Number of events 64 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
14.8%
46/311 • Number of events 66 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.4%
5/205 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Infections and infestations
Urinary tract infection
|
2.3%
5/216 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
4.6%
10/217 • Number of events 11 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
4.7%
10/215 • Number of events 12 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
13.5%
43/318 • Number of events 69 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
15.1%
47/311 • Number of events 87 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
6.3%
13/205 • Number of events 17 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Investigations
Alanine aminotransferase increased
|
1.4%
3/216 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.4%
3/217 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.3%
5/215 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
5.3%
17/318 • Number of events 27 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
7.4%
23/311 • Number of events 34 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.5%
3/205 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Investigations
Aspartate aminotransferase increased
|
1.4%
3/216 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.47%
1/215 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
3.5%
11/318 • Number of events 15 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
6.1%
19/311 • Number of events 29 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.98%
2/205 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/216 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.3%
5/217 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
4.2%
9/215 • Number of events 9 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
10.1%
32/318 • Number of events 57 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
18.6%
58/311 • Number of events 81 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
3.4%
7/205 • Number of events 7 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.46%
1/216 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/217 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.4%
3/215 • Number of events 3 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
5.7%
18/318 • Number of events 19 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
6.4%
20/311 • Number of events 23 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.4%
5/205 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
4.6%
10/216 • Number of events 11 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.46%
1/217 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.3%
5/215 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
14.2%
45/318 • Number of events 60 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
9.3%
29/311 • Number of events 39 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
4.4%
9/205 • Number of events 11 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Skin and subcutaneous tissue disorders
Rash
|
1.9%
4/216 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.92%
2/217 • Number of events 2 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
1.9%
4/215 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.5%
8/318 • Number of events 10 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
6.4%
20/311 • Number of events 24 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.49%
1/205 • Number of events 1 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
|
Vascular disorders
Hypertension
|
1.9%
4/216 • Number of events 4 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.3%
5/217 • Number of events 5 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
0.00%
0/215 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
8.8%
28/318 • Number of events 30 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
8.0%
25/311 • Number of events 26 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
2.9%
6/205 • Number of events 6 • Up to 5 years
Adverse Event collection in Period 2 combined the Periods 1+2 Upadacitinib 15 mg Arm which includes 101 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 217 participants who started in the Period 1 Upadacitinib 15 mg Arm. The Upadacitinib 30 mg Arm includes 96 participants who were re-randomized from the Period 1 Methotrexate Arm in addition to the 215 participants who started in the Period 1 Upadacitinib 30 mg Arm
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
- Publication restrictions are in place
Restriction type: OTHER